Danaher Corporation
DHRDanaher Corporation (NYSE: DHR) is a global science and technology company based in the United States. Its primary business focus is organized into two core reporting segments: Life Sciences and Diagnostics. The Life Sciences segment provides a range of instruments, reagents, and software used by researchers to study the basic building blocks of life, including cells and nucleic acids, and to develop new therapies. This includes technologies for bioprocessing, genomics, and lab productivity. The Diagnostics segment offers analytical instruments, reagents, and software for clinical laboratories to analyze samples and diagnose diseases. The company operates through a decentralized model, managing a portfolio of over 20 operating companies, each with its own specialized brand. These subsidiaries serve critical areas within the healthcare and scientific research ecosystems. Key areas addressed by Danaher's products and services include molecular diagnostics, pathology, microbiology, and immunochemistry. The company's platforms are utilized in research, clinical, and industrial settings, supporting work in areas such as infectious disease testing, cancer diagnosis, and biopharmaceutical manufacturing. As a publicly traded entity, Danaher's strategic acquisitions and subsequent integration of businesses into its Danaher Business System (DBS) management philosophy have been central to its growth. The company’s products and services are used worldwide by hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.
DHR · Stock Price
Historical price data
About
Danaher Corporation (NYSE: DHR) is a global science and technology company based in the United States. Its primary business focus is organized into two core reporting segments: Life Sciences and Diagnostics. The Life Sciences segment provides a range of instruments, reagents, and software used by researchers to study the basic building blocks of life, including cells and nucleic acids, and to develop new therapies. This includes technologies for bioprocessing, genomics, and lab productivity. The Diagnostics segment offers analytical instruments, reagents, and software for clinical laboratories to analyze samples and diagnose diseases. The company operates through a decentralized model, managing a portfolio of over 20 operating companies, each with its own specialized brand. These subsidiaries serve critical areas within the healthcare and scientific research ecosystems. Key areas addressed by Danaher's products and services include molecular diagnostics, pathology, microbiology, and immunochemistry. The company's platforms are utilized in research, clinical, and industrial settings, supporting work in areas such as infectious disease testing, cancer diagnosis, and biopharmaceutical manufacturing. As a publicly traded entity, Danaher's strategic acquisitions and subsequent integration of businesses into its Danaher Business System (DBS) management philosophy have been central to its growth. The company’s products and services are used worldwide by hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.